
Fulgent Genetics, Inc. – NASDAQ:FLGT
Fulgent Genetics stock price today
Fulgent Genetics stock price monthly change
Fulgent Genetics stock price quarterly change
Fulgent Genetics stock price yearly change
Fulgent Genetics key metrics
Market Cap | 555.76M |
Enterprise value | 870.71M |
P/E | 6.83 |
EV/Sales | 1.40 |
EV/EBITDA | 3.89 |
Price/Sales | 1.50 |
Price/Book | 0.73 |
PEG ratio | -0.09 |
EPS | -5.57 |
Revenue | 287.53M |
EBITDA | -46.34M |
Income | -165.94M |
Revenue Q/Q | -2.54% |
Revenue Y/Y | -21.19% |
Profit margin | 23.17% |
Oper. margin | 29.32% |
Gross margin | 59.28% |
EBIT margin | 29.32% |
EBITDA margin | -16.12% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFulgent Genetics stock price history
Fulgent Genetics stock forecast
Fulgent Genetics financial statements
Jun 2023 | 67.85M | -11.22M | -16.55% |
---|---|---|---|
Sep 2023 | 84.68M | -13.10M | -15.48% |
Dec 2023 | 70.50M | -128.14M | -181.76% |
Mar 2024 | 64.48M | -13.46M | -20.88% |
Sep 2025 | 81.83M | -4.00M | -4.89% |
---|---|---|---|
Oct 2025 | 82.85M | -4.82M | -5.82% |
Dec 2025 | 85.48M | -8.53M | -9.99% |
Mar 2026 | 83.11M | -8.20M | -9.88% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 1354577000 | 91.25M | 6.74% |
---|---|---|---|
Sep 2023 | 1358398000 | 96.56M | 7.11% |
Dec 2023 | 1273109000 | 139.82M | 10.98% |
Mar 2024 | 1229885000 | 103.23M | 8.39% |
Jun 2023 | 9.73M | -1.09M | -16.25M |
---|---|---|---|
Sep 2023 | 10.24M | 20.07M | -4.47M |
Dec 2023 | 14.93M | 24.27M | -25.95M |
Mar 2024 | 7.26M | -47.18M | -2.80M |
Fulgent Genetics alternative data
Fulgent Genetics Social Media Accounts
May 2025 | 1137 |
---|---|
Jul 2025 | 1147 |
Aug 2025 | 1171 |
Next Generation Sequencing
12 Feb 2023 | 60 |
---|---|
19 Feb 2023 | 51 |
26 Feb 2023 | 55 |
5 Mar 2023 | 49 |
12 Mar 2023 | 71 |
19 Mar 2023 | 43 |
26 Mar 2023 | 71 |
2 Apr 2023 | 56 |
9 Apr 2023 | 69 |
16 Apr 2023 | 45 |
23 Apr 2023 | 70 |
30 Apr 2023 | 66 |
7 May 2023 | 45 |
14 May 2023 | 63 |
21 May 2023 | 54 |
28 May 2023 | 60 |
4 Jun 2023 | 51 |
11 Jun 2023 | 57 |
18 Jun 2023 | 60 |
25 Jun 2023 | 64 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
Aug 2023 | 4 |
---|---|
Sep 2023 | 2 |
Oct 2023 | 3 |
Nov 2023 | 1 |
Dec 2023 | 3 |
Jan 2024 | 6 |
Feb 2024 | 5 |
Apr 2024 | 2 |
May 2024 | 67 |
Jun 2024 | 66 |
Jul 2024 | 70 |
Aug 2023 | 1,012 |
---|---|
Sep 2023 | 1,012 |
Oct 2023 | 1,012 |
Nov 2023 | 1,012 |
Dec 2023 | 1,012 |
Jan 2024 | 1,012 |
Feb 2024 | 1,012 |
Mar 2024 | 1,184 |
Apr 2024 | 1,184 |
May 2024 | 1,184 |
Jun 2024 | 1,184 |
Jul 2024 | 1,184 |
Fulgent Genetics other data
Period | Buy | Sel |
---|---|---|
Aug 2024 | 0 | 4324 |
Sep 2024 | 0 | 4771 |
Nov 2024 | 0 | 3413 |
Dec 2024 | 0 | 2828 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | XIE JIAN officer: Presiden.. | Common Stock | 1,455 | $19.5 | $28,373 | ||
Sale | GAO HANLIN officer: Chief Scientific Officer | Common Stock | 1,373 | $19.5 | $26,774 | ||
Sale | HSIEH MING director, 10 perc.. | Common Stock | 2,227 | $18.26 | $40,663 | ||
Sale | GAO HANLIN officer: Chief Scientific Officer | Common Stock | 497 | $18.26 | $9,075 | ||
Sale | XIE JIAN officer: Presiden.. | Common Stock | 689 | $18.26 | $12,580 | ||
Sale | KIM PAUL officer: CFO and .. | Common Stock | 1,674 | $21.96 | $36,763 | ||
Sale | XIE JIAN officer: Presiden.. | Common Stock | 1,594 | $21.96 | $35,006 | ||
Sale | GAO HANLIN officer: Chief Scientific Officer | Common Stock | 1,503 | $21.96 | $33,007 | ||
Sale | GAO HANLIN officer: Chief Scientific Officer | Common Stock | 563 | $22.83 | $12,855 | ||
Sale | XIE JIAN officer: Presiden.. | Common Stock | 715 | $22.83 | $16,326 |
Quarter | Transcript |
---|---|
Q1 2024 3 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Paul Kim (1967) Chief Financial Officer | $253,660 |
Mr. Ming Hsieh (1956) Chairman, Chief Executive Officer & Pres | $248,000 |
Mr. Jian Xie (1966) Chief Operating Officer | $224,540 |
Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. (1967) Chief Scientific Officer & Laboratory Director | $223,510 |
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Fulgent Genetics: Growth Is Returning
Fulgent Genetics: Navigating Post-COVID Growing Pains
Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone
What To Expect From Fulgent Genetics In 2023
Fulgent Genetics: Attractive Valuation, But I Prefer To Hold For Now
Fulgent Genetics: Surviving The Covid Cliff
NeoGenomics: What The Leadership Shuffle Means
At EV/Sales Below 1x, Fulgent Is Undervalued
-
What's the price of Fulgent Genetics stock today?
One share of Fulgent Genetics stock can currently be purchased for approximately $21.57.
-
When is Fulgent Genetics's next earnings date?
Unfortunately, Fulgent Genetics's (FLGT) next earnings date is currently unknown.
-
Does Fulgent Genetics pay dividends?
No, Fulgent Genetics does not pay dividends.
-
How much money does Fulgent Genetics make?
Fulgent Genetics has a market capitalization of 555.76M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 53.27% to 289.21M US dollars.
-
What is Fulgent Genetics's stock symbol?
Fulgent Genetics, Inc. is traded on the NASDAQ under the ticker symbol "FLGT".
-
What is Fulgent Genetics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Fulgent Genetics?
Shares of Fulgent Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Fulgent Genetics's key executives?
Fulgent Genetics's management team includes the following people:
- Mr. Paul Kim Chief Financial Officer(age: 58, pay: $253,660)
- Mr. Ming Hsieh Chairman, Chief Executive Officer & Pres(age: 69, pay: $248,000)
- Mr. Jian Xie Chief Operating Officer(age: 59, pay: $224,540)
- Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. Chief Scientific Officer & Laboratory Director(age: 58, pay: $223,510)
-
How many employees does Fulgent Genetics have?
As Jul 2024, Fulgent Genetics employs 1,184 workers.
-
When Fulgent Genetics went public?
Fulgent Genetics, Inc. is publicly traded company for more then 8 years since IPO on 29 Sep 2016.
-
What is Fulgent Genetics's official website?
The official website for Fulgent Genetics is fulgentgenetics.com.
-
Where are Fulgent Genetics's headquarters?
Fulgent Genetics is headquartered at 4978 Santa Anita Avenue, Temple City, CA.
-
How can i contact Fulgent Genetics?
Fulgent Genetics's mailing address is 4978 Santa Anita Avenue, Temple City, CA and company can be reached via phone at +62 635 00537.
Fulgent Genetics company profile:

Fulgent Genetics, Inc.
fulgentgenetics.comNASDAQ
1,184
Medical - Diagnostics & Research
Healthcare
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Temple City, CA 91780
CIK: 0001674930
ISIN: US3596641098
CUSIP: 359664109